
	Chemical structure search How to Search	Import MOLfile format is only available (V3000 format is not available) Exact match Substructure search Superstructure search Substructure or superstructure search Similarity search

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr

J-GLOBAL ID：201601013404236618 Update date: Feb. 01, 2025

Sakai Hitomi

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research theme for competitive and other funds (1)：

2022 - 2025 Assessment of cerebrospinal fluid ctDNA for the development of systemic therapy for brain metastases and leptomeningea disease of HER2-negative breast cancer

Papers (47)：

Farhat Jawhara, Sakai Hitomi, Tsurutani Junji. Management of nausea and vomiting induced by antibody-drug conjugates. Breast cancer (Tokyo, Japan). 2025
Hitomi Sakai, Junji Tsurutani, et al. A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Annals of Oncology. 2024
Miyazaki N, Iwasaki T, Sakai H, et al. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Curr Med Res Opin. 2024. 40. 5
Terada Mitsuo, Ito Aki, Kikawa Yuichiro, Koizumi Kei, Naito Yoichi, Shimoi Tatsunori, Ishihara Mikiya, Yamanaka Takashi, Ozaki Yukinori, Hara Fumikata, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast cancer (Tokyo, Japan). 2023. 30. 6
Hiroko Masuda, Yuko Tanabe, Hitomi Sakai, Koji Matsumoto, Akihiko Shimomura, Mihoko Doi, Yasuo Miyoshi, Masato Takahashi, Yasuaki Sagara, Shinya Tokunaga, et al. Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). Breast (Edinburgh, Scotland). 2023. 71. 22-28

MISC (47)：

鶴谷純司, 酒井瞳. The mechanisms of resistance against ADCs, to overcome. 月刊腫瘍内科. 2023. 32. 5
Meiko Nishimura, Takahiro Kogawa, Yuko Akaishi, Misato Ogata, Jun Masuda, Mitsuo Terada, Hitomi Sakai, Kazuki Nozawa, Sasagu Kurozumi, Takamichi Yokoe, et al. Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients. CANCER RESEARCH. 2022. 82. 4
Yoshio Itani, Hitomi Sakai, Mikiko Asai-Sato, Shinya Sato, Masayuki Futagami, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Tetsutaro Hamano, Yoshio Yoshida. A post-hoc study of relative dose intensity in elderly patients with advanced ovarian cancer (JGOG3016-A3). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
吉田好雄, 二神真行, 酒井瞳, 鈴木直. 婦人科がん臨床研究のトレンドを知る 9.婦人科悪性腫瘍研究機構(JGOG):支持・緩和医療. 産科と婦人科. 2020. 87. 6. 675-680
金村宙昌, 林秀敏, 萩原智, 酒井瞳, 米阪仁雄, 中川和彦. アテゾリズマブによる多臓器障害に対して血漿交換を使用した一例. 肺癌. 2019. 59. 6. 779-779

Books (3)：

Lectures and oral presentations (16)：

1816O - A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
(ESMO congress 2024 2024)
Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID)
(JSMO2024 2024)
WJOG (West Japan Oncology Group)Breast Cancer Consensus Meeting 2023
(JSMO2024 2024)
Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B
(JSMO2024 2024)
A randomized, double-blind, placebo-controlled study of olanzapine for CINV during T-DXd in HER2 positive metastatic breast cancer patients: WJOG14320B (ERICA)
(GBCC 2023)

Committee career (4)：

2022/04 - 2024/03 Western Japan Oncology Group (WJOG), Breast Cancer Young Researchers Group BRIGHT, Representative
2022/10 - Japanese Breast Cancer Society, Clinical Practice Guidelines Committee, Drug Therapy Subcommittee
婦人科悪性腫瘍研究機構(JGOG)支持緩和医療委員
Japanese Society of Supportive Care in Cancer, Guideline Development Committee for Appearance Care Guidelines in Cancer Treatment, 2021 Edition

Awards (2)：

Association Membership(s) (4)：

American Society of Clinical Oncology , 日本乳癌学会 , 日本臨床腫瘍学会 , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.


	Free word	※Add the following synonyms, you can increase the number of hits.




		～